Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Aug;10(8):1323-39.
doi: 10.2217/pgs.09.53.

Pharmacogenomics of CYP3A: considerations for HIV treatment

Sukhwinder S Lakhman  1 , Qing Ma, Gene D Morse
Affiliations
Review

Pharmacogenomics of CYP3A: considerations for HIV treatment

Sukhwinder S Lakhman et al. Pharmacogenomics. 2009 Aug.

Abstract

The understanding of the cytochrome P450 3A SNP in antiretroviral therapy is important, because it is highly inducible, extremely polymorphic and metabolizes many of the drugs that are key components of highly active antiretroviral therapy regimens. This enzyme is prolific and promiscuous towards drug and xenobiotic substrate selection and it is also unpredictable among individuals, having a 5- to 20-fold variability in its ability to contribute to drug clearance. The importance of human CYP3A pharmacogenetics is also gaining attention in other established areas of pharmacotherapy as it may contribute to the goal of predicting efficacy and/or toxicity, specifically with the discovery of null allele CYP3A4*20. This review summarizes the current understanding, implications of genetic variation in the CYP3A enzymes, the central role of CYP3A in linking human genetics, the pharmacokinetics and resulting pharmacodynamic responses to certain antiretroviral drugs, and their eventual place in applied clinical pharmacotherapy.

PubMed Disclaimer

References

    1. van Heeswijk RP. Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics. Expert Rev Anti Infect Ther. 2003;1:75–81. - PubMed
    1. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002;18:825–834. - PubMed
    1. Catanzaro L, Slish J, Dicenzo R, Morse G. Drug interactions with antiretrovirals. Curr HIV/AIDS Rep. 2004;1:89–96. - PubMed

    2. ▪ Along with [4] provides the comprehensive insight into the drug interaction in antiretroviral therapy.

    1. Boffito M, Acosta E, Burger D, et al. Therapeutic drug monitoring and drug–drug interactions involving antiretroviral drugs. Antivir Ther. 2005;10:469–477. - PubMed

    2. ▪ Along with [3] provides the comprehensive insight into the drug interaction in antiretroviral therapy.

    1. Wertheimer BZ, Freedberg KA, Walensky RP, Yazdanapah Y, Losina E. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials. 2006;7:59–69. - PubMed

Publication types

MeSH terms